

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that, it has executed an agreement with the remaining shareholders in Alkahest Inc. ("**Alkahest**") to acquire the remaining shares of Alkahest (approximately 55%) in exchange of a total price of \$146 million, on a debt free basis. No additional financing will be required. The closing of the transaction is subject to the approval by the relevant antitrust authorities, and is expected to take place in early 2021. Grifols already acquired a stake of approximately 45% of Alkahest in March 2015. With this transaction, Grifols gains total control of Alkahest.

Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and disease.

The transaction is part of Grifols' commitment with the research and development of therapeutic alternatives designed to contribute to both scientific and social development. In addition, it is aligned with Grifols' strategy of complementing its range of existing plasma protein therapies and diagnostic products to treat and diagnose serious diseases and to extend the quality of human life.

In Barcelona, on 7 September 2020

Nuria Martín Barnés
Secretary to the Board of Directors